Sector
PharmaceuticalsOpen
₹505.05Prev. Close
₹513.15Turnover(Lac.)
₹249.42Day's High
₹521.9Day's Low
₹505.0552 Week's High
₹645.7552 Week's Low
₹431.05Book Value
₹136.57Face Value
₹10Mkt Cap (₹ Cr.)
4,783.38P/E
33.21EPS
15.43Divi. Yield
0.226 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
4 Sep 2023
12:00 AM
AGM
Announcement Date: 04 Sep, 2023
24 Jan 2024
12:00 AM
Dividend
Dividend Amount: 1
Record Date: 06 Feb, 2024
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 92.6 | 92.6 | 93.2 | 23.3 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,021.7 | 879.57 | 766.41 | 598.49 |
Net Worth | 1,114.3 | 972.17 | 859.61 | 621.79 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,251.17 | 1,914.89 | 1,634.92 | 1,140.45 |
yoy growth (%) | 17.56 | 17.12 | 43.35 | 4.75 |
Raw materials | -1,480.52 | -1,139.91 | -1,045.87 | -700.52 |
As % of sales | 65.76 | 59.52 | 63.97 | 61.42 |
Employee costs | -69.31 | -69.28 | -60.09 | -50.48 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 255.49 | 337.48 | 166.59 | 112.21 |
Depreciation | -47.39 | -47.59 | -46.66 | -37.79 |
Tax paid | -60.5 | -80 | -39.3 | -38.8 |
Working capital | 194.84 | 155.99 | 28.06 | 98.02 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 17.56 | 17.12 | 43.35 | 4.75 |
Op profit growth | -20.7 | 64.17 | 34.4 | 3.66 |
EBIT growth | -23.47 | 81.13 | 36.89 | 2.07 |
Net profit growth | -24.33 | 89.94 | 84.81 | -2.73 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 2,528.58 | 2,716.05 | 2,488.65 | 2,154.78 | 1,806.09 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,528.58 | 2,716.05 | 2,488.65 | 2,154.78 | 1,806.09 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.03 | 2.19 | 11.32 | 4.74 | 5.95 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
CMD & Executive Director
Prakash M Patil
ED / MD / Promoter
Rashesh C Gogri
ED / Joint MD / Promoter
Harshit M Savla
E D & Wholetime Director
Harit P Shah
WTD & Executive Director
Uday M Patil
Non Executive Director
Narendra Jagannath Salvi
Independent Non Exe. Director
Navin Chapshi Shah
Independent Non Exe. Director
Krishnacharya G Akamanchi
Independent Non Exe. Director
Priti Savla
Independent Non Exe. Director
Ankit Vikram Paleja
Independent Non Exe. Director
Bhaskar Narayan Thorat
Independent Non Exe. Director
Neha Gada
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Aarti Drugs Ltd
Summary
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for im
Read More
What is the Aarti Drugs Ltd share price today?
The Aarti Drugs Ltd shares price on N/A is Rs.₹519 today.
What is the Market Cap of Aarti Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Drugs Ltd is ₹4771.43 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Aarti Drugs Ltd?
The PE and PB ratios of Aarti Drugs Ltd is 33.21 and 4.01 as of 22 Jul ‘24
What is the 52 Week High and Low of Aarti Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Aarti Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Aarti Drugs Ltd is ₹430 and ₹645 as of 22 Jul ‘24
What is the CAGR of Aarti Drugs Ltd?
Aarti Drugs Ltd's CAGR for 5 Years at 33.28%, 3 Years at -10.74%, 1 Year at -1.08%, 6 Month at -3.63%, 3 Month at 3.27% and 1 Month at -1.82%.
What is the shareholding pattern of Aarti Drugs Ltd?
The shareholding pattern of Aarti Drugs Ltd is as follows:
Promoters - 55.67 %
Institutions - 10.31 %
Public - 34.02 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
